Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$236.97 USD

236.97
597,597

-1.09 (-0.46%)

Updated Oct 3, 2024 03:59 PM ET

After-Market: $232.00 -4.97 (-2.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Myriad Genetics' EndoPredict Gets Positive Coverage Decision

Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.

    Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance

    The new acquisition deal with Rite Aid would enable Walgreens (WBA) to buy nearly half of its business at a deal value, almost one-third of the original price. Downsides remain a challenge.

      Fluidigm (FLDM) Licenses CFTR Assay From Baylor Genetics

      Fluidigm (FLDM) has licensed rights to commercialize the cystic fibrosis transmembrane conductance regulator. The company is focused on improving its Juno automated microfluidic system.

        Allscripts, Elligo Health Enter in Strategic Partnership

        Allscripts' (MDRX) Strategic Partnership with Elligo Health would aid the company in capturing the Clinical Research Organizations' lucrative market.

          Walgreens' (WBA) Research Website to Add Value in Healthcare

          Walgreens Boots Alliance's (WBA) Center for Health & Wellbeing Research is set to improve patient care and outcomes while reducing health care costs at the same time.

            Omnicell Upgrades Web Portal, Grows in Medication Management

            Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.

              Henry Schein to Offer CAEK's HIPAA Software LayerCompliance

              Henry Schein (HSIC) inks an agreement to distribute CAEK's HIPAA related software, LayerCompliance.

                Here's Why Investors Should Buy Edwards Lifesciences Now

                Market is upbeat about Edwards Lifesciences's (EW) recent FDA approvals and strong 2017 guidance.

                  Here's Why Investors Should Buy Align Technology (ALGN) Now

                  Align Technology (ALGN) continues to ride high on robust growth in the Invisalign space.

                    Intuitive Surgical at 52-Week High: What's Driving the Stock?

                    Share price of Intuitive Surgical (ISRG) reaches a new 52-week high on the back of its new partnership and impressive second-quarter performance.

                      Medtronic Announces RESOLUTE ONYX ONE-MONTH DAPT Study

                      Medtronic (MDT) announces a clinical trial to evaluate one-month dual antiplatelet therapy in patients implanted with the Resolute Onyx Drug-Eluting Stent during PCI procedures.

                        Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

                        Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.

                          Varian (VAR) Rides on Oncology and Proton Therapy Businesses

                          Varian Medical's (VAR) oncology and Proton therapy business' growth prospects remain impressive. However, competition in the radiotherapy space raise concern.

                            Civitas Solutions (CIVI) Q3 Earnings Beat, Revenues Miss

                            Civitas Solutions (CIVI) gains on strength in Post-Acute Specialty Rehabilitation Services and Adult Day Health services in Q3. However, tweaked full-year 2017 guidance signals dull prospects.

                              Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes

                              Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                                STERIS (STE) Banks on Organic Growth, Competition Intense

                                STERIS' (STE) cost structure is likely to be enhanced through recent organizational changes.

                                  Why Brookdale Senior Living (BKD) Could Be Positioned for a Slump

                                  One stock that you may want to consider dropping is Brookdale Senior Living Inc. (BKD), which has witnessed a significant price decline in the past four weeks.

                                    AmerisourceBergen's PharMEDium Slows Down, Competition Rife

                                    AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.

                                      STAAR Surgical (STAA) Catches Eye: Stock Moves 8.3% Higher

                                      STAAR Surgical Company (STAA) moved big last session, as its shares jumped over 8% on the day.

                                        Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation

                                        Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation

                                          BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife

                                          The company achieved annualized supply chain improvement since the acquisition of Home Solutions.

                                            OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2

                                            OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

                                              Kevin Cook headshot

                                              The $200 Club: Will Facebook Beat Alibaba There First?

                                              When you find great fundamental growth stories that institutions must own, you can buy and trade them for a long time in a bull market.

                                                CVS Health Grows on Specialty Pharmacy amid Retail Woes

                                                CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.

                                                  Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

                                                  Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.